Published in Am J Cancer Res on February 15, 2012
How many neutrophils are enough (redux, redux)? J Clin Invest (2012) 0.76
A biased competition theory of cytotoxic T lymphocyte interaction with tumor nodules. PLoS One (2015) 0.75
On Study of Immune Response to Tumor Cells in Prey-Predator System. Int Sch Res Notices (2014) 0.75
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Cancer regression in patients after transfer of genetically engineered lymphocytes. Science (2006) 16.96
Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol (2011) 9.19
Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol (1998) 8.40
Skin cancers after organ transplantation. N Engl J Med (2003) 6.65
Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74
Mechanisms of immune evasion by tumors. Adv Immunol (2006) 5.34
The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer (2011) 3.45
Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science (1991) 2.81
Prognostic significance of tumor-infiltrating T-lymphocytes in primary and metastatic lesions of advanced stage ovarian cancer. Cancer Immunol Immunother (2008) 2.54
Next generation of immunotherapy for melanoma. J Clin Oncol (2008) 1.69
Cancer vaccines. Immunol Today (1993) 1.67
Modeling immunotherapy of the tumor-immune interaction. J Math Biol (1998) 1.62
Cyclophosphamide augments antitumor immunity: studies in an autochthonous prostate cancer model. Cancer Res (2009) 1.51
Comparing interferon- gamma release assay with tuberculin skin test readings at 48-72 hours and 144-168 hours with use of 2 commercial reagents. Clin Infect Dis (2004) 1.48
White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res (2011) 1.27
Radiotherapy augments the immune response to prostate cancer in a time-dependent manner. Prostate (2008) 1.17
Immune and clinical outcomes in patients with stage IV melanoma vaccinated with peptide-pulsed dendritic cells derived from CD34+ progenitors and activated with type I interferon. J Immunother (2005) 1.11
Controlled release, biodegradable cytokine depots: a new approach in cancer vaccine design. Cancer Res (1993) 1.03
Macrophage T lymphocyte interactions in the anti-tumor immune response: a mathematical model. J Immunol (1985) 0.94
Betting on immunotherapy for melanoma. Curr Oncol Rep (2009) 0.89
Current state of vaccine therapies in non-small-cell lung cancer. Clin Lung Cancer (2008) 0.89
The humoral immune response to Haemophilus influenzae type b: a mathematical model based on T-zone and germinal center B-cell dynamics. J Theor Biol (1998) 0.84
Molecular profiling of melanoma and the evolution of patient-specific therapy. Semin Oncol (2011) 0.84
Rational development of tumour antigen-specific immunization in melanoma. Ther Immunol (1995) 0.81
Review of interleukin-2 alone and interleukin-2/LAK clinical trials in metastatic malignant melanoma. Cancer Treat Rev (1989) 0.80
Adoptive immunotherapy of patients with metastatic renal cell cancer using lymphokine-activated killer cells, interleukin-2 and cyclophosphamide: long-term results. Int J Urol (1998) 0.80
Immunology and disease control: a systems approach. IEEE Trans Biomed Eng (1994) 0.80
Dependence on antigen dose and timing in the immune response of C3H mice to malignant ascites cells. Immunology (1980) 0.77